Clinical Trials
4 trialsNCT06141031 2026-05-27
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
Phase 1 Recruiting
NCT05440708 2026-04-27
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Tvardi Therapeutics, Incorporated
Phase 1/2 Recruiting
NCT05668949 2025-12-17
Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT05845307 2025-12-08
Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Withdrawn